Abstracts tagged "Glucocorticoids and polymyalgia rheumatica"

Abstract Number: 2197 • 2018 ACR/ARHP Annual Meeting
Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
Paula Estrada¹, Patricia Moya², Hector Corominas³, Delia Reina⁴, Dacia Cerdà⁴, Daniel Roig Vilaseca⁴, Vanessa Navarro⁴, Sergi Heredia⁴ and Francisco Javier Narváez⁵, ¹Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral,, barcelona, Spain, ⁵Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain
Background/Purpose: Giant cell arteritis (GCA) and polymialgia rheumatica (PMR) are overlapping inflammatory diseases. Large Vessel Vasculitis (LVV) is frequently present in any of the two…
Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Elisheva Pokroy-Shapira¹, Ariela Dortort-Lazar^2,3 and Yair Molad^4,5, ¹Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Beilinson hospital Rabin Medical Center, Petah Tikva, Israel, ³Sackler Faculty of Medicine Tel Aviv university, Tel Aviv, Israel, ⁴Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…
Abstract Number: 1176 • 2017 ACR/ARHP Annual Meeting
A Randomized, Open-Label, Dose-Ranging Study of Oral Delayed Release Prednisone in Patients with Untreated Polymyalgia Rheumatica
Jasvinder A. Singh¹ and Lee S. Simon², ¹Medicine, University of Alabama at Birmingham, Alabama, AL, ²SDG LLC Consulting, West Newton, MA
Background/Purpose: Polymyalgia rheumatica (PMR) is a common condition of unknown etiology with a lifetime risk of 2.43% in women and 1.66% in men.1 PMR is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].